Stromal Expression Profiling Reveals Immune‐Driven Adaption to Malignancy in Canine Melanoma Subtypes
Veterinary and Comparative Oncology · 2025
DOI: 10.1111/vco.13021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2025. Verfasst von Erin Beebe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Dog Diseases, Melanoma, Skin Neoplasms, Mouth Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edoardo R., Giovanni, Giuseppe und Chiarina Sassella-Stiftung, Kurt und Senta Herrmann Stiftung, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Canine mucosal melanoma (CMM) is the most common oral malignancy in dogs and is significantly more aggressive than its cutaneous counterpart (CCM), yet the reasons for this disparity remain unclear. Cancer‐associated stroma (CAS) plays a crucial role in tumour progression, but a detailed understanding of CAS in canine melanoma is missing. To assess stromal reprogramming, we analysed CAS from 21 CMM, 14 CCM and normal stroma from 10 skin and 9 oral mucosa samples by laser‐capture microdissection followed by RNA sequencing. Results were assessed in relation to subtypes, prognostic factors including mitotic count (MC), ulceration, necrosis, pigmentation and immune cell infiltration (CD3, CD20 and CD68), scored using immunohistochemistry and RNA in situ hybridisation. Stromal reprogramming was evident in both subtypes but significantly more pronounced in CMM. Immune‐excluded tumours exhibited higher MC than desert/cold ones. MC strongly correlated with genes associated with B‐cells, T‐helper cells and CTLA4 in CCM, suggesting CAS reprogramming to depend on tumour malignancy. Finally, we identify an immune‐suppressive stromal signature in a subset of CMM characterised by the downregulation of key immune checkpoints and pathways. Together, these findings provide a solid foundation for understanding the role of CAS in canine melanoma, specific to cutaneous and mucosal subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
- Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
- The Royal (Dick) School of Veterinary Studies and the Roslin Institute, Midlothian, UK.
ORCID-Profile: Erin Beebe
Förderung
- Edoardo R., Giovanni, Giuseppe und Chiarina Sassella-Stiftung
- Kurt und Senta Herrmann Stiftung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Beebe, E., Krudewig, C., Motamed, Z., Malbon, A., & Markkanen, E. (2025). Stromal Expression Profiling Reveals Immune‐Driven Adaption to Malignancy in Canine Melanoma Subtypes. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.13021
Vancouver
Beebe E, Krudewig C, Motamed Z, Malbon A, Markkanen E. Stromal Expression Profiling Reveals Immune‐Driven Adaption to Malignancy in Canine Melanoma Subtypes. Veterinary and Comparative Oncology. 2025. doi:10.1111/vco.13021
BibTeX
@article{Beebe2025,
author = {Beebe, Erin and Krudewig, Christiane and Motamed, Zahra and Malbon, Alexandra and Markkanen, Enni},
title = {Stromal Expression Profiling Reveals Immune‐Driven Adaption to Malignancy in Canine Melanoma Subtypes},
journal = {Veterinary and Comparative Oncology},
year = {2025},
doi = {10.1111/vco.13021}
}
EUVIMED